12 August 2019


Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces the following change in the non-beneficial ownership of the ordinary shares in the Company held by James Barder, the Company's Chief Executive.

Futura today received notification that Mr. Barder has resigned as a trustee of a family trust. No Futura shares have been sold or distributed by the trust.

As a result, Mr Barder's non-beneficial holding is revised to 117,500 ordinary shares. His beneficial holding remains unchanged at 968,472 ordinary shares with an aggregate beneficial and non-beneficial holding of 1,085,972 ordinary shares, representing approximately 0.53% per cent. of the Company's issued share capital.

Further details are contained within the notification below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014.

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670

Nominated Adviser and Sole Broker:

Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000

For media enquiries please contact:

Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144

 

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name James Barder
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Futura Medical plc
b) LEI 21380053QLT46UNV2303
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Identification code Ordinary Shares of 0.2 pence each GB0033278473
b) Nature of the transaction Change in non-beneficial holding as a result of resignation from a family trust.
c) Price(s) and volume(s)
Price(s) Volume(s)
N/A 117,500
d) Aggregated information
- Aggregated volume
- Price
N/A
e) Date of the transaction 12 August 2019
f) Place of the transaction Outside a trading venue